The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Getting the Shingrix vaccine after the age of 50 can reduce your chances of developing the painful skin condition known as ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

The research collaboration, which will take four years to complete, will use population-level electronic health data from the NHS to assess the impact of GSK’s recombinant zoster vaccine Shingrix on ...

GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate whether GSK’s shingles vaccine, Shingrix (zoster vaccine recombinant ...